-
Je něco špatně v tomto záznamu ?
Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - The 2020 COVID-19 pandemic: A statement from the EAACI-section on pediatrics
HA. Brough, O. Kalayci, A. Sediva, E. Untersmayr, D. Munblit, P. Rodriguez Del Rio, M. Vazquez-Ortiz, S. Arasi, M. Alvaro-Lozano, S. Tsabouri, E. Galli, B. Beken, PA. Eigenmann,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, přehledy
PubMed
32319129
DOI
10.1111/pai.13262
Knihovny.cz E-zdroje
- MeSH
- akademie a ústavy MeSH
- alergie terapie MeSH
- Betacoronavirus * MeSH
- COVID-19 MeSH
- dítě MeSH
- kojenec MeSH
- koronavirové infekce prevence a kontrola MeSH
- lidé MeSH
- mladiství MeSH
- pandemie prevence a kontrola MeSH
- pediatrie metody MeSH
- předškolní dítě MeSH
- SARS-CoV-2 MeSH
- směrnice pro lékařskou praxi jako téma MeSH
- syndromy imunologické nedostatečnosti terapie MeSH
- virová pneumonie prevence a kontrola MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- předškolní dítě MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Geografické názvy
- Evropa MeSH
While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and healthcare providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, and bronchodilators, increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic, and immunodeficient children should be sought according to usual treatment guidelines. This statement of the EAACI Section on Pediatrics puts forward six recommendations for the management of childhood allergies and immunodeficiencies based on six underlying facts and existing evidence.
Allergy and Clinical Immunology Department Hospital Sant Joan de Déu Universitat de Barcelona Spain
Allergy Department Hospital Infantil Universitario Niño Jesus Madrid Spain
Child Health Department University of Ioannina School of Medicine Ioannina Greece
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028068
- 003
- CZ-PrNML
- 005
- 20241217095521.0
- 007
- ta
- 008
- 210105s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/pai.13262 $2 doi
- 035 __
- $a (PubMed)32319129
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Brough, Helen A $u Department of Women and Children's Health, Children's Allergy Service, Evelina Children's Hospital, Guy's and St. Thomas' Hospital NHS Foundation Trust, Paediatric Allergy Group, School of Life Course Sciences, King's College London, London, UK.
- 245 10
- $a Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - The 2020 COVID-19 pandemic: A statement from the EAACI-section on pediatrics / $c HA. Brough, O. Kalayci, A. Sediva, E. Untersmayr, D. Munblit, P. Rodriguez Del Rio, M. Vazquez-Ortiz, S. Arasi, M. Alvaro-Lozano, S. Tsabouri, E. Galli, B. Beken, PA. Eigenmann,
- 520 9_
- $a While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and healthcare providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, and bronchodilators, increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic, and immunodeficient children should be sought according to usual treatment guidelines. This statement of the EAACI Section on Pediatrics puts forward six recommendations for the management of childhood allergies and immunodeficiencies based on six underlying facts and existing evidence.
- 650 _2
- $a akademie a ústavy $7 D000047
- 650 _2
- $a mladiství $7 D000293
- 650 12
- $a Betacoronavirus $7 D000073640
- 650 _2
- $a COVID-19 $7 D000086382
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a koronavirové infekce $x prevence a kontrola $7 D018352
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a alergie $x terapie $7 D006967
- 650 _2
- $a syndromy imunologické nedostatečnosti $x terapie $7 D007153
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a pandemie $x prevence a kontrola $7 D058873
- 650 _2
- $a pediatrie $x metody $7 D010372
- 650 _2
- $a virová pneumonie $x prevence a kontrola $7 D011024
- 650 _2
- $a směrnice pro lékařskou praxi jako téma $7 D017410
- 650 _2
- $a SARS-CoV-2 $7 D000086402
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kalayci, Omer $u Hacettepe University School of Medicine, Ankara, Turkey.
- 700 1_
- $a Sediva, Anna $u Department of Immunology, 2nd Medical Faculty, Charles University and Motol University Hospital, Prague, Czech Republic.
- 700 1_
- $a Untersmayr, Eva $u Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Munblit, Daniel $u Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia. Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, UK.
- 700 1_
- $a Rodriguez Del Rio, Pablo $u Allergy Department, Hospital Infantil Universitario Niño Jesus, Madrid, Spain.
- 700 1_
- $a Vazquez-Ortiz, Marta $u Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, UK.
- 700 1_
- $a Arasi, Stefania $u Pediatric Allergology Unit, Department of Pediatric Medicine, Bambino Gesù Children's research Hospital (IRCCS), Rome, Italy.
- 700 1_
- $a Alvaro-Lozano, Montserrat $u Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Spain.
- 700 1_
- $a Tsabouri, Sophia $u Child Health Department, University of Ioannina School of Medicine, Ioannina, Greece.
- 700 1_
- $a Galli, Elena $u Pediatric Allergology Unit, Department of Pediatric Medicine, S.Pietro Hospital Fatebenefratelli, Rome, Italy.
- 700 1_
- $a Beken, Burcin $u Department of Pediatric Allergy and Immunology, Istanbul Health Sciences University Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, Turkey.
- 700 1_
- $a Eigenmann, Philippe $u Pediatric Allergy Unit, Department of Woman, Child and Adolescent, University Hospitals of Geneva, Geneva, Switzerland. $7 xx0326824
- 773 0_
- $w MED00010395 $t Pediatric allergy and immunology $x 1399-3038 $g Roč. 31, č. 5 (2020), s. 442-448
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32319129 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20241217095517 $b ABA008
- 999 __
- $a ok $b bmc $g 1608403 $s 1119248
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 31 $c 5 $d 442-448 $e 20200531 $i 1399-3038 $m Pediatric allergy and immunology $n Pediatr Allergy Immunol $x MED00010395
- LZP __
- $a Pubmed-20210105
